Development of a unilateral ureteral obstruction model in cynomolgus monkeys

Linghong Huang | Jia Ni | Tanika Duncan | Zhizhan Song | Timothy S. Johnson

Abstract

Background: Chronic kidney disease (CKD) has a high global prevalence and large unmet need. Central to developing new CKD therapies are in vivo models in CKD. However, next-generation antibody, protein, and gene therapies are highly specific, meaning some do not cross-react with rodent targets. This complicates preclinical development, as established in vivo rodent models cannot be utilized unless tool therapeutics are also developed. Tool compounds can be difficult to develop and, if available, typically have different epitopes, sequences, and/or altered affinity, making it unclear how efficacious the lead therapeutic may be, or what dosing regimen to investigate. To address this, we aimed to develop a nonhuman primate model of CKD.

Methods: In vivo rodent unilateral ureteral obstruction (UUO) models kidney fibrosis and is commonly used due to its rapidity, consistency, and ease. We describe translation of this model to the cynomolgus monkey, specifically optimizing the model duration to allow adequate time for assessment of novel therapeutics prior to the fibrotic plateau.

Results: We demonstrated that disease developed more slowly in cynomolgus monkeys than in rodents post-UUO, with advanced fibrosis developing by 6 weeks. The tubulointerstitial fibrosis in cynomolgus monkeys was more consistent with human obstructive disease than in rodents, having a more aggressive tubular basement expansion and a higher fibroblast infiltration. The fibrosis was also associated with increased transglutaminase activity, consistent with that seen in patients with CKD.

Conclusion: This cynomolgus monkey UUO model can be used to test potential human-specific therapeutics in kidney fibrosis.

Keywords

animal models, fibrosis, kidney, nonhuman primates, transglutaminase

1 INTRODUCTION

Chronic kidney disease (CKD) is one of the most common diseases worldwide with kidney fibrosis being a histological hallmark. Several animal models of CKD have been developed to understand pathogenesis and verify disease targets for therapeutic treatment.

Unilateral ureteral obstruction (UUO) is a model resembling human obstructive nephropathy. Although it is not a common cause of human renal disease, it is a well-recognized and frequently used model of kidney damage with subsequent fibrosis development. By ligating a ureter of one kidney, the build-up of urine elevates intratubular pressure; this results in reduction in renal blood flow and...
glomerular filtration rate, as well as other changes such as interstitial inflammation, tubular dilation, tubular atrophy, and ultimately, fibrosis. Rodent UUO models have been utilized to investigate mechanisms of tubulointerstitial fibrosis, with severe fibrosis being detected within 21 days.\(^6\)\(^7\)

Development of fibrosis in the rodent UUO model is associated with changes in extracellular glutaminase (TG)\(^8\) and is a hallmark of human disease pathology.\(^7\) TG2 is a calcium-dependent enzyme that crosslinks extracellular matrix (ECM) proteins to form a stable and proteolytic resistant ε(γ-glutamyl)-lysine dipeptide cross-link.\(^10\) This increased crosslinking in ECM accelerates the rate of ECM deposition, while making it less susceptible to degradation by ECM proteases. Increases in extracellular TG2 expression, TG activity, and ε(γ-glutamyl)-lysine dipeptide crosslinks have been demonstrated in all types of human CKD, and are highly correlated with fibrosis levels.\(^7\) Studies performed using rodent models of kidney fibrosis have shown increased TG2 and that blocking its activity slows renal fibrosis.\(^8\),\(^11\)\(^-\)\(^13\) A study is currently underway to evaluate inhibition of TG2 in patients with CKD (NCT04335578). TG2 is therefore a useful mechanistic tool to evaluate if the pathological processes of CKD occurring in an in vivo model are consistent with those in humans.

Although some proteins are homologous between species, antibodies targeting functional human epitopes (i.e., therapeutic antibodies) can be highly species-specific as they often recognize conformational epitopes, whereby changes in a single amino acid in the epitope can raise affinity and lower half-maximal inhibitory concentration (IC\(_{50}\)) significantly. Therefore, antibodies optimized for human proteins may not sufficiently cross-react with other species to allow testing in commonly used rodent in vivo models. An option to mitigate this is to use a surrogate tool antibody; however, binding at a different epitope may complicate interpretation of data, provide different pharmacokinetics and thus, less valuable translational data to predict efficacious doses in early clinical studies. It is becoming increasingly important to use models in species with high homology and close physiology to humans to evaluate next-generation therapeutic antibodies and other modalities where species homology plays a significant role such as gene, small interfering RNA (siRNA), and oligonucleotide therapies. The non-human primates (NHP) most commonly used in medical research are from the genus Macaca, or more specifically the cynomolgus monkey. Their consensus with the human proteome\(^1\) allows a high degree of cross-reactivity, making them a suitable species for studies with highly specific antibodies or other new therapeutic modalities. Models of liver\(^1\) and lung fibrosis have been established in cynomolgus monkeys and there are NHP models of renal transplantation/rejection.\(^37\) However, to date, there are no models of renal fibrosis in NHP. Therefore, we hypothesized that a cynomolgus monkey UUO model could be developed and validated. The UUO model surgery is simple (compared with other models such as 5/6th subtotal nephrectomy) and the remaining functional kidney prevents problems with organ failure and any associated welfare issues such as end-stage renal failure. Translating the UUO model from mice to rats to rabbits was relatively consistent and quick; thus, we did not anticipate issues in translating the model to cynomolgus monkeys. Given the biggest variable between species when using the UUO model is the time to develop fibrosis consistent with end-stage renal disease, we undertook a time-course evaluation of tubulointerstitial fibrosis post-UUO to understand the optimal duration of the model and evaluate expression of a human-relevant pathological process currently being tested in the clinic: TG2.

## 2 | MATERIALS AND METHODS

### 2.1 | Animal methods

Fourteen male cynomolgus monkeys (Hainan Jingang Biotech Co. Ltd., China) were used in the study. All animals were tuberculosissensitive and free of viral, bacterial, or parasitic infections (including simian immunodeficiency virus, respiratory syncytial virus, simian-T-lymphotropic virus, tuberculosis, Schmallenberg virus, shigellosis, and salmonellosa). Adult monkeys (aged 7–8 years) were used in this study to more accurately model human disease. Common tests for kidney disease were performed to ensure that the animals had no proteinuria (urinary protein <10 mg/dl, test with visual urinary test strip) or loss of renal function (serum creatinine <100 µmol/L, blood urea nitrogen <9 mmol/L) at study initiation.

Each monkey was housed in a stainless steel cage with a minimum living area of length 160 cm \(\times\) depth 80 cm \(\times\) height 190 cm at 18–29°C with a relative humidity of 40%–70% and had access to the exercise cage sized 480 \(\times\) 80 \(\times\) 190 cm for 24 h each week (1 animal per cage). Monkeys had free access to monkey chow (Guangzhou Guolong Science & Technology Co. Ltd., China) and municipal tap water meeting drinking standards; vegetables and fruit treats were also given daily to stimulate their appetite.

The 14 cynomolgus monkeys were randomized (simple randomization method) into 5 groups: 1 consisting of 2 sham-operated animals (harvested at week 6; one time point was sufficient for the sham population, to confirm that no fibrosis occurred at the maximum time point) and 4 groups of 3 animals undergoing UUO and kept for experimental periods of 3, 4, 5, or 6 weeks after surgery. Sham animals received laparotomy only and animals in the UUO groups had the left ureter occluded with a double silk tie. Animals were fasted for 12 h and water withheld for 3 h prior to general anesthesia. Anesthesia was induced by intramuscular (IM) injection of 5 mg/kg Zoletil 50 (Virbac, Carros, France) initially and maintained using 5% isoflurane inhalation. Prior to a midline incision in the abdominal wall, fur was shaved and skin disinfected. The ureter of the left kidney was dissected and ligated at 2 adjacent points by silk ties and the abdominal wall subsequently closed. To minimize infection, 25 000 IU/kg of penicillin was given by IM injection twice daily for 3 days. The analgesia regimen applied is listed in Table 1. Animals were closely monitored post-surgery; their appearance, body weight, temperature, respiratory rate, and behavior were assessed daily and their skin wound checked by an onsite vet every day until it healed. All UUO animals were provided with soft bedding after...
surgery until normal behavior resumed (scored and recorded during each observation). In general, the UUO surgical procedure was associated with moderate pain, and all animals recovered within a few days. At harvest, animals were euthanized by intravenous injection of 80 mg/kg pentobarbital, and kidneys dissected longitudinally and each half cut into 4 segments. One segment from each half kidney was fixed in 10% neutral formalin solution and embedded in paraffin blocks. The other segments were snap frozen and used for in situ TG activity, extracellular TG2 staining, and hydroxyproline detection. Researchers performing sample analysis did not know the group allocation until data were generated.

2.2 | Picrosirius red and Masson's trichrome stain

Neutral-buffered, formalin-fixed, paraffin-embedded 4 μm sections were dewaxed and rehydrated. Nuclei were stained with Weigert's hematoxylin (Sigma Aldrich, UK), washed in water, and stained in Picrosirius red (PSR) solution for 1 h prior to being washed in acidified water. Sections were dehydrated and cleaned using a series of alcohols and xylenes and then mounted in dibutylphthalate polystyrene xylene (DPX). Masson's trichrome stain was then performed using a kit (Sigma Aldrich, UK) as per manufacturer instructions (stains collagenous material blue, nuclei brown and fibers, erythrocytes and elastin red/pink).

2.3 | In situ TG activity

Detection of in situ TG activity was performed as described previously with some modification. Frozen kidney tissues were mounted in optimal cutting temperature (OCT) mounting media (VWR International, UK) and cut at 10 μm thickness. Unfixed sections were washed in phosphate-buffered saline (PBS) and incubated with reconstitution PBS made up of 5% BSA with protease inhibitors for 30 min at room temperature prior to being incubated with a mouse anti-human TG2 antibody (IA12; generated recombinantly in-house at UCB, using the sequences described in patent WO/2013/175229 and used previously for analytical work) at a concentration of 30 μg/mL for 1 h at 37°C. Sections were washed 3 times with PBS, fixed in cold acetone for 5 min, and air dried. These were then washed with PBS before a goat anti-mouse Alexa 488 antibody (Thermo Fisher Scientific, UK), diluted 1 in 500 in 5% BSA/PBS, was added. After incubation for 1 h at 37°C, sections were washed in PBS and mounted with anti-fade mounting medium containing DAPI.

2.4 | Extracellular TG2 antigen staining

Immunodetection of extracellular TG2 was performed as previously described. Frozen kidney tissues were mounted in OCT mounting media and cut at 10 μm thickness. Unfixed sections were washed in PBS, and blocked in PBS buffer made up of 5% BSA with protease inhibitors for 30 min at room temperature prior to being incubated with a mouse anti-human TG2 antibody (IA12; generated recombinantly in-house at UCB, using the sequences described in patent WO/2013/175229 and used previously for analytical work) at a concentration of 30 μg/mL for 1 h at 37°C. Sections were washed 3 times with PBS, fixed in cold acetone for 5 min, and air dried. These were then washed with PBS before a goat anti-mouse Alexa 488 antibody (Thermo Fisher Scientific, UK), diluted 1 in 500 in 5% BSA/PBS, was added. After incubation for 1 h at 37°C, sections were washed in PBS and mounted with anti-fade mounting medium containing DAPI.
2.6 | Hydroxyproline analysis

Kidney homogenates containing 5 mg of protein per sample were hydrolyzed in 6 mol/L hydrochloric acid at 110°C for 24 h. These were centrifuged at 18 000 g for 2 min and the supernatant transferred to clean tubes and freeze dried. Samples were resuspended in 500 µl of lithium loading buffer (Biochrom, UK) and 30 µl fractionated using a lithium chloride gradient on a Biochrom 30+ amino acid analyzer using the manufacturer’s standard protocol and expressed as µmol/mg protein.

2.7 | Measurement of ε-(γ-glutamyl)-lysine crosslink

Kidney homogenate containing 10 mg of protein from each animal was subjected to exhaustive proteolytic digestion with subtilisin, pronase, leucine amino peptidase, prolidase, and carboxypeptidase Y. Measurement of ε-(γ-glutamyl)-lysine crosslinks was performed using cation exchange chromatography on an amino acid analyzer (Biochrom, UK).

2.8 | Statistical analysis

Raw data are shown with each symbol representing one animal. Data analyses were performed using one-way analysis of variance (ANOVA) by a Fisher’s least significant difference multiple comparisons test (GraphPad Prism). A significance level of 5% (p < .05) was adopted throughout.

3 | RESULTS

3.1 | Kidney fibrosis

At 6 weeks, UUO in cynomolgus monkeys caused changes mainly in the tubulointerstitium, as expected. From week 3 onwards, under low magnification (Figure 2, upper panel), key changes observed were tubular dilation and increased collagen accumulation, shown as blue on the Masson’s trichrome stained images. Using higher-power magnification (Figure 2, lower panel), it was possible to observe flattened and elongated tubular epithelial cells leading to dilated tubules with loss of the brush border. Thickening of the tubular basement membrane was particularly clear and notably in excess of that seen in rodent UUO models, as well as increased cell numbers in the expanded tubulointerstitial space. Compared with the sham, these changes were relatively mild in the 3-week group, but progressed in severity through weeks 4 and 5, peaking at week 6. Of note, there was significant expansion of the tubular basement between weeks 3 and 4, which seemed to expand little after week 4 where tubular destruction and atrophy became the main histological changes. Fibrotic changes, especially tubulointerstitial expansion, was confirmed by PSR-stained sections (Figure 3). Image analysis was performed to quantify levels of fibrosis. All UUO groups had increased fibrosis, reaching significance in the 4- and 6-week UUO groups (Figure 4A).

Hydroxyproline is a major component of collagen and can be used as an easily quantifiable surrogate of the total amount of collagen present in the kidney. In this cynomolgus monkey
model, significantly elevated hydroxyproline was detected in the UUO kidneys from week 4 onwards (Figure 4B). Compared with the sham, levels of hydroxyproline were increased by 1.5-fold at week 3, more than double at week 4 and peaked with a 2.6-fold change at weeks 5 and 6.

3.2 | **In situ TG activity, extracellular TG2 expression and levels of ε-(γ-glutamyl)-lysine crosslink**

In the healthy (sham) kidney, low TG activity was seen in the glomeruli and tubular basement membrane/tubulointerstitial space, based...
on incorporation of the labeled TG substrate (biotin cadaverine) (Figure 5A). Activity increased 3 weeks post-UUO, with an elevation in substrate incorporation in the expanded tubulointerstitial space at 4 weeks post-UUO. TG activity at 5 and 6 weeks post-UUO continued to increase (Figure 5A) in contrast to TG2 extracellular antigen, which plateaued at weeks 5 and 6 (Figure 5B). When image analysis was performed to quantify changes in TG activity, 3-, 6-, and 8-fold increases were seen at weeks 4, 5, and 6, respectively (Figure 5C).

In the kidneys of healthy (sham) cynomolgus monkeys, small amounts of extracellular TG2 were detected and located in the tubular basement membrane/tubulointerstitial space, periglomerular area and mesangial matrix (Figure 5B). In the kidneys of cynomolgus monkeys
with UUO, changes in extracellular TG2 expression were mainly focused around tubules and associated with the tubular basement membrane (Figure 5B). Elevation in extracellular TG2 antigen reached a maximum at 4 weeks post-UUO and remained at that level for the remainder of the study. Quantification of the image analysis indicated that extracellular TG2 increased in the kidneys of cynomolgus monkeys with UUO from 3 weeks onwards, with significant changes compared with the sham group at 4, 5, and 6 weeks post-UUO (Figure 5D).

Analysis of ε-(γ-glutamyl)-lysine crosslink in kidneys with UUO showed a progressive trend of elevated crosslink dipeptide that reached a maximum at 5 weeks post-UUO and remained high to week 6 (Figure 5E).

### 3.3 Correlations between levels of in situ TG activity versus ε-(γ-glutamyl)-lysine crosslink and hydroxyproline

Correlation between in situ TG activity and ε-(γ-glutamyl)-lysine crosslink was $r = .52$ (Figure 6A). There was also a correlation between in situ TG activity and hydroxyproline, strongly linking the accumulation of collagen with TG2 in this model ($r = .82$, Figure 6B).

### 4 DISCUSSION

This study sought to transfer the UUO model of CKD from rodents to cynomolgus monkeys, with the aim of allowing development of human-specific therapeutics, not cross-reactive with rodents and with a novel mode of action, for which in vivo pharmacological data are essential to define dosing for phase I human studies. Understanding the time course of the disease process was key to allowing optimal selection of study duration and relating this to changes in collagen levels (and thus fibrosis), while using TG2 as an exemplar molecule of clinical stage target in CKD. The model was developed in adult animals to assist with translation, as CKD is typically a disease of later life in which changes occur in multiple parameters associated with fibrosis, including cell senescence, promoter methylation, ECM homeostasis, and hemodynamics.

Overall, these data demonstrate a clear development of tubulointerstitial fibrosis over the 3- to 6-week study period, although data from the different methods used to assess the extent of fibrosis in this study were not totally aligned. Manual assessment of the sections would suggest fibrosis progressed over the 6-week study period, approaching end-stage remodeling around or just after week 6. Image analysis of PSR suggested that the level of interstitial collagens plateau from week 4 onwards, whereas total kidney hydroxyproline is progressive until week 5. In terms of TG2, the level of activity progressed over the 6 weeks, with maximum extracellular TG2 antigen reached by week 4, and the formation of ε-(γ-glutamyl)-lysine peaking at week 5. This poses the question of the optimal time to run the model when being used to test interventional efficacy. It is generally accepted that the level of fibrosis will ultimately reach a plateau in non-functional models such as the UUO. Therefore, model duration must be optimized to allow the maximum window for measurement of interventional success before the linear formation of scar tissue declines and hides any beneficial effect on slowing progression of fibrosis. Based on the composite data here, a 4-week model in aged cynomolgus monkeys would provide the optimal balance between the disease window and the slowing of histological and mechanistic changes that underpin fibrosis. However, given the heterogeneity of data due to the intentionally small animal numbers used, it is possible that the optimal duration of this model to maximize the disease window could be 5 weeks.

Although the data allow us to conclude successful model development, there are 3 reasons for the variability observed in some of our data. Firstly, there are ethical considerations associated with any study in primates. It is important to use the smallest number of animals possible; however, it was difficult to calculate the absolute minimum number required as there is no precedent or data on which to base power
FIGURE 5  Changes in TG2 in cynomolgus monkey UUO kidneys. In situ TG activity (A) was detected on unfixed kidney cryostat sections by the incorporation of biotin cadaverine, which was revealed using a streptavidin-Alexa 555 conjugate. TG activity is represented by yellow and nuclei stained as blue. Extracellular TG2 (B) was detected on unfixed kidney cryostat sections. TG2 antigen is represented by green and nuclei stained as blue. In situ TG activity (C) and extracellular TG2 (D) in the kidney cortex was quantified using Definiens Tissue Studio software. Levels of activity and TG2 expression were calculated by measuring the area of yellow and green staining. Values were corrected for cell number by calculating this as a fraction of the blue staining of nuclei. ε-(γ-glutamyl)-lysine crosslink (E) was measured by releasing the dipeptide from 10 mg protein using exhaustive proteolytic digestion followed by cation exchange chromatography on an amino acid analyzer (Biochrom). Raw data are presented with the line indicating the mean. * and ** indicate $p < .05$ and $p < .01$, respectively (one-way ANOVA). TG, transglutaminase; UUO, unilateral ureteral obstruction.
HUANG et al.

To better standardize the baseline clinical parameters, we aimed to develop a model in adult animals (7–8 years old) to more accurately model human disease. However, adult animals are more likely to have preexisting diseases; as such, all animals were pre-screened for serum creatinine, blood urea nitrogen, and urine protein using a test strip, and only animals with results within a normal range were positively correlated with changes in collagen quantity. Therefore, despite reducing variability where possible, breeding from parents not closely related introduces genetic variation, adding significant heterogeneity to the system.

Despite variability in the data, we were able to make some key observations about the effect of UUO of the kidneys. Fibrotic changes in the kidney cortex shown by image analysis of PSR staining were consistent with levels of fibrosis, reaching a plateau from 4 weeks post-UUO. This is slightly different to the hydroxyproline data that showed fibrosis reached plateau at 5 weeks post-UUO, while visual histopathological assessment was progressive over the 6-week period. The difference between collagen measures may be due to medullary tissue being included when hydroxyproline was measured but excluded in the PSR analysis in stained sections. Visually, the expansion of the tubular basement membrane reached a maximum at around 4 weeks, whereas disease progression is more often associated with subsequent tubular atrophy. As the tubular basement membrane area would be the primary parameter in high content image analysis of PSR, it is not surprising to note small increases in staining post 4 weeks. In addition, changes in TG activity do not seem to chronologically match levels of extracellular TG2 in the UUO kidney, with progressive TG activity over 6 weeks and TG2 antigen plateauing from 4 weeks post-UUO. However, TG2 in the extracellular space may not be active, with studies showing rapid deactivation of extracellular TG2\(^{25}\) or TG2 being kept in its inactive state by binding to heparan sulphate proteoglycans such as syndecan 4.\(^{26}\) Thus, it is possible that there was a higher percentage of active TG2 in the UUO kidney at the later stages. Importantly, levels of in situ TG activity were positively correlated with changes in collagen quantity.

In conclusion, this study has successfully transitioned the rodent UUO model of CKD to a NHP. The model progresses to completion in approximately 6 weeks compared with 3 weeks in mice and rat models, with a suggestion that an optimal study period for testing therapeutics to avoid disease plateauing would be 4 weeks. The NHP model demonstrates a much more aggressive tubular interstitial fibrosis than rodents, with a larger expansion of the tubular basement membrane and greater infiltration of interstitial cells giving a histological picture closer to obstructive disease in humans. This NHP model can be applied to test human-specific anti-fibrotic therapeutic molecules to determine efficacy, target engagement, and pharmacokinetics.

ACKNOWLEDGMENTS

The authors would like to thank Annick Cauvin for her constructive advice during her review of the manuscript. The authors acknowledge Veronica Porskess, PhD, of UCB Pharma, for publication and editorial support. The authors also acknowledge Sarah Hibbert, PhD, of Ashfield MedComms, an Ashfield Health company, for editing support that was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
CONFLICT OF INTEREST
L.H., T.D., and T.S.J. are employees of UCB Pharma and may hold/have access to stock options. Z.S. is an employee of Prisys Biotechnologies Co., Ltd., and J.N. was employed by Prisys Biotechnologies Co., Ltd. at the time this work was conducted.

AUTHOR CONTRIBUTIONS
All authors reviewed the manuscript and approved the final version for submission. L.H. was the lead scientist and wrote the manuscript. She developed, optimized, and ran the various analyses used as well as collating and analyzing the data generated. J.N. helped design the study and the ran the in-life phase of the investigation. T.D. performed Masson’s trichrome and Picrosirus staining. Z.S. directed the animal study at Prisys Biotechnologies. T.J. designed the study, commissioned the work, and edited the manuscript.

STATEMENT OF ETHICS
Animal work was approved by Prisys Institutional Animal Care and Use Committee under study number 2015-PS11-002 (license code SYXX-2014-007). UCB representatives (including the company-named animal care and welfare officer) assessed facilities and procedures at Prisys Biotechnologies before commencement of studies to ensure that all were compatible with UK Home Office guidelines, for the use of experimental animals as defined under the Animal Scientific Procedures Act 1986 (ASPL), and that current ‘best practice’ in animal welfare was being applied. A UCB representative was subsequently present during all experimental procedures to ensure full compliance with ASPL.

ORCID
Timothy S. Johnson https://orcid.org/0000-0003-2238-3463

REFERENCES
1. Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol. 2012;27(6):901-909. doi:10.1007/s00467-011-1992-9
2. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 2013;304(3):C216-C225. doi:10.1152/ajpcell.00328.2012
3. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002;283(5):F861-F875. doi:10.1152/ajprenal.00362.2001
4. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75(11):1052-1058. doi:10.1038/ki.2009.86
5. Ucero AC, Benito-Martin A, Izuquierdo MC, et al. Unilateral ureteral obstruction: beyond obstruction. Int Urol Nephrol. 2014;46(4):765-776. doi:10.1007/s11255-013-0520-1
6. Edgerton KL, GowRM, KellyDJ, CarmelietP, RichardKitchingA. Plasmin is not protective in experimental renal interstitial fibrosis 1. Kidney Int. 2004;66(1):68-76. doi:10.1111/j.1523-1755.2004.00707.x
7. Guo J, Wu W, Sheng M, Yang S, Tan J. Amygdalin inhibits renal fibrosis in chronic kidney disease. Mol Med Rep. 2013;7(5):1453-1457. doi:10.3892/mmr.2013.1391
8. Scarpellini A, Huang L, Burhan I, et al. Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis. J Am Soc Nephrol. 2014;25(5):1013-1027. doi:10.1681 ASN.2013050563
9. Johnson TS, El-Koraie AF, Skill NJ, et al. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol. 2003;14(8):2052-2062. doi:10.1097/01ASN.0000079614.63463.dd
10. Fisher M, Jones RA, Huang L, et al. Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol. 2009;28(1):20-31. doi:10.1016/j.matbio.2008.10.003
11. Johnson TS, Griffin M, Thomas GL, et al. The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest. 1997;99(12):2950-2960. doi:10.1172/JCI119490
12. Johnson TS, Skill NJ, El Nahas AM, et al. Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol. 1999;10(10):2146-2157.
13. Huang L, Haylor JL, Hau Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 2009;76(4):383-394. doi:10.1038/ki.2009.230
14. Yan G, Zhang G, Fang X, et al. Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques. Nat Biotechnol. 2011;29(11):1019-1023. doi:10.1038/nbt.1992
15. Ding KE, Liu M-R, Li J, et al. Establishment of a liver fibrosis model in cynomolgus monkeys. Exp Toxicol Pathol. 2014;66(5-6):257-261. doi:10.1016/j.etp.2014.03.003
16. Manabe J, Ogata T. Lung fibrosis induced by diquat after intratracheal administration. Arch Toxicol. 1987;60(6):427-431. doi:10.1007/BF00302385
17. Anderson DJ, Kirk AD. Primate models in organ transplantation. Cold Spring Harb Perspect Med. 2013;3(9):a015503. doi:10.1101/cshperspect.a015503
18. Johnson T, Watson P, Matthews D, Brown A, inventors. Anti-transglutaminase 2 antibodies. 2012. Patent number: WO/2013/175229.
19. Susnik N, Sen P, Melk A, Schmitt R, Aging, cellular senescence, and kidney fibrosis. Curr Pathobiol Rep. 2017;5(2):123-131. doi:10.1007/s40139-017-0143-9
20. Zhou B, Wan Y, Chen R, et al. The emerging role of cellular senescence in renal diseases. J Cell Mol Med. 2020;24(3):2087-2097. doi:10.1111/jcmm.14952
21. Larkin BP, Glastras SJ, Chen H, Pollock CA, Saad S. DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease. FASEB J. 2018;32(10):5215-5226. doi:10.1096/fj.201800205R
22. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011;4(2):165-178. doi:10.1242/dmm.004077
23. Griffin KA, Bidani AK. Hypertension and kidney damage. J Clin Hypertens. 2006;8(3):209-214. doi:10.1111/j.1524-6175.2005.05111.x
24. Siegel M, Strnad P, Watts RE, et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One. 2008;3(3):e1861. doi:10.1371/journal.pone.0001861
25. Lortat-Jacob H, Burhan I, Scarpellini A, et al. Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix. J Biol Chem. 2012;287(22):18005-18017. doi:10.1074/jbc.M111.337089

How to cite this article: Huang L, Ni J, Duncan T, Song Z, Johnson TS. Development of a unilateral ureteral obstruction model in cynomolgus monkeys. Anim Models Exp Med. 2021;4:359-368. doi:10.1002/ame2.12185